Introduction
Materials and methods
Study design
Data collection
Statistical analysis
Data processing
Variables | Before imputation(mean ± standard deviation) | After imputation(mean ± standard deviation) | P value |
---|---|---|---|
Weight, kg | 64.8 ± 10.2 | 64.8 ± 10.1 | 0.953 |
Height, cm | 172.0 ± 6.1 | 172.0 ± 6.1 | 0.828 |
BMI, kg/m2 | 21.9 ± 3.0 | 21.8 ± 3.0 | 0.564 |
WBC, 109/L | 5.7 ± 2.0 | 5.7 ± 2.0 | 0.991 |
PLT, 109/L | 188.7 ± 62.5 | 188.6 ± 62.5 | 0.961 |
HB, g/L | 142.7 ± 30.9 | 142.7 ± 30.9 | 0.995 |
CR, mmol/L | 71.3 ± 19.4 | 71.3 ± 19.4 | 0.932 |
TG, mmol/L | 1.7 ± 2.3 | 1.7 ± 2.3 | 0.928 |
TC, mmol/L | 4.3 ± 1.3 | 4.3 ± 1.3 | 0.976 |
FBG, mmol/L | 5.6 ± 1.3 | 5.6 ± 1.3 | 0.922 |
AST, U/L | 27.0 ± 27.2 | 27.1 ± 27.2 | 0.955 |
ALT, U/L | 30.2 ± 29.2 | 30.2 ± 29.2 | 0.986 |
TBIL, mmol/L | 12.0 ± 6.2 | 12.0 ± 6.2 | 0.964 |
Establishment and validation of prediction model
Presentation of nomogram
Results
Establishment of prediction model
Variable | Training set (N = 420) | Validation set (N = 180) | P value |
---|---|---|---|
Continuous variables | |||
Age, year | 50.00 (40.00,57.00) | 48.00 (37.75,61.00) | 0.376 |
Interval from onset to diagnosis, day | 52.00 (33.00,159.50) | 46.50 (26.00,149.00) | 0.107 |
ALT, U/L | 21.65 (15.57,32.92) | 22.15 (16.00,32.65) | 0.629 |
AST, U/L | 22.15 (17.90,30.33) | 23.45 (18.95,31.23) | 0.173 |
BMI, kg/m2 | 21.85 (19.84,23.94) | 21.48 (19.24,23.68) | 0.106 |
CD4, cells/μL | 259.50 (111.50,384.50) | 243.50 (101.00,377.25) | 0.79 |
TC, mmol/L | 4.15 (3.55,4.82) | 4.12 (3.48,4.80) | 0.559 |
CR, μmol/L | 69.00 (61.00,77.00) | 69.00 (59.83,78.00) | 0.778 |
FBG, mmol/L | 5.60 (5.10,6.09) | 5.37 (4.91,5.92) | 0.051 |
HB, g/L | 136.00 (119.75,151.00) | 136.00 (117.75,152.25) | 0.956 |
PLT, 109/L | 172.00 (137.00,213.25) | 167.50 (135.75,219.00) | 0.808 |
TBIL, μmol/L | 10.25 (7.80,14.00) | 10.30 (6.80,13.40) | 0.203 |
TG, mmol/L | 1.38 (1.03,1.87) | 1.32 (0.96,1.97) | 0.458 |
WBC, 109/L | 5.20 (4.10,6.38) | 5.04 (4.01,6.38) | 0.475 |
Discrete variables | |||
Gender, n(%) | |||
Male | 386 (91.90) | 160 (88.89) | 0.276 |
Female | 34 (8.10) | 20 (11.11) | |
Hepatitis B Virus, n(%) | |||
Negative | 390 (92.86) | 170 (94.44) | 0.593 |
Positive | 30 (7.14) | 10 (5.56) | |
Hepatitis C Virus, n(%) | |||
Negative | 413 (98.33) | 178 (98.89) | 0.731 |
Positive | 7 (1.67) | 2 (1.11) | |
Marital status, n(%) | |||
Unmarried | 68 (16.19) | 42 (23.33) | 0.05 |
Married | 352 (83.81) | 138 (76.67) | |
Shingles, n(%) | |||
No | 375 (89.29) | 165 (91.67) | 0.458 |
Yes | 45 (10.71) | 15 (8.33) | |
Infection route, n(%) | |||
Homosexual transmission | 240 (57.14) | 98 (54.44) | 0.77 |
Heterosexual transmission | 122 (29.05) | 54 (30.00) | |
Other transmission | 58 (13.81) | 28 (15.56) | |
Baseline TB, n(%) | |||
No | 407 (96.90) | 175 (97.22) | 1.00 |
Yes | 13 (3.10) | 5 (2.78) | |
WHO clinical stage, n(%) | |||
I, II | 189 (45.00) | 75 (41.67) | 0.655 |
III | 102 (24.29) | 43 (23.89) | |
IV | 129 (30.71) | 62 (34.44) | |
Continuous or intermittent fever, n(%) | |||
No | 387 (92.14) | 167 (92.78) | 0.868 |
Yes | 33 (7.86) | 13 (7.22) | |
Continuous diarrhea (> one month), n(%) | |||
No | 397 (94.52) | 165 (91.67) | 0.202 |
Yes | 23 (5.48) | 15 (8.33) |
Variables | Univariable | Multivariable | ||
---|---|---|---|---|
HR (95%CI) | P value | AHR (95%CI) | P value | |
Female | 1.364 (0.686,2.712) | 0.376 | ||
Marital Status (Married) | 0.83 (0.496,1.388) | 0.478 | ||
Infection route | ||||
Homosexual transmission | Ref | Ref | Ref | Ref |
Heterosexual transmission | 1.551 (0.984,2.446) | 0.059# | 1.327 (0.821, 2.145) | 0.248 |
Other transmission | 1.979 (1.142,3.428) | 0.015* | 1.193 (0.661, 2.154) | 0.478 |
Baseline TB | 2.024 (0.821,4.986) | 0.125# | 1.264 (0.491, 3.255) | 0.584 |
HBV (Negative) | 0.619 (0.227,1.689) | 0.349 | ||
HCV (Negative) | 0.702 (0.098,5.04) | 0.725 | ||
Continuous diarrhea (> one month) | 2.478 (1.286,4.775) | 0.007* | 2.271 (1.088, 4.742) | 0.058 |
Continuous or intermittent fever | 2.028 (1.141,3.605) | 0.016* | 0.905 (0.448, 1.680) | 0.628 |
Shingles | 1.905 (1.138,3.187) | 0.014* | 1.965 (1.140, 3.390) | 0.018* |
WHO clinical stage | ||||
I, II | Ref | Ref | – | – |
III | 1.572 (0.908,2.721) | 0.106# | – | – |
IV | 2.692 (1.678,4.318) | < .001*** | – | – |
Age, year | 1.007 (0.99,1.023) | 0.424 | ||
Interval from onset to diagnosis, day | 1.000 (1.000,1.000) | 0.564 | ||
CD4, cells/μL | 0.995 (0.994,0.997) | < .001*** | 0.996 (0.995, 0.0.998) | < .001*** |
BMI, kg/m2 | 0.795 (0.74,0.853) | < .001*** | 0.875 (0.809, 0.946) | < .001*** |
WBC, 109/L | 0.969 (0.888,1.057) | 0.476 | ||
PLT, 109/L | 0.998 (0.995,1.001) | 0.254 | ||
HB, g/L | 0.968 (0.961,0.975) | < .001*** | 0.975 (0.965, 0.984) | < .001*** |
CR, μmol/L | 1.002 (1,1.005) | 0.099# | 1.002 (0.999, 1.005) | 0.175 |
TG, mmol/L | 0.963 (0.849,1.093) | 0.562 | ||
TC, mmol/L | 0.707 (0.57,0.877) | 0.002* | 0.821 (0.670, 1.006) | 0.038* |
FBG, mmol/L | 0.731 (0.59,0.905) | 0.004* | 0.938 (0.769, 1.145) | 0.442 |
AST, U/L | 1.011 (1.006,1.017) | < .001*** | 1.001 (0.989, 1.014) | 0.951 |
ALT, U/L | 1.008 (1.002,1.014) | 0.008* | 1.002 (0.992, 1.012) | 0.647 |
TBIL, mmol/L | 0.991 (0.957,1.027) | 0.617 |